EGFR and adenocarcinoma: TMB was comparable between EGFR-mutant SCC and adenocarcinoma patients (7.61 vs. 5.99 mutations/Mb, P=0.565), the median TMB (mTMB) was 7.61 (95% CI: 5.84–13.40) and 5.99 (95% CI: 5.77–11.13) mutations/Mb, respectively.